Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
CAMBRIDGE, Mass., Feb. 18, 2016 -- Proteostasis Therapeutics, Inc. today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share. All of the shares sold in the offering were offered by Proteostasis Therapeutics, Inc. The company’s shares began trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol “PTI.” The gross proceeds from the offering are $50.0 million, before deducting underwriting discounts and commissions and expenses associated with the offering payable by the company.
Leerink Partners and RBC Capital Markets acted as joint book-running managers. Baird and H.C. Wainwright & Co. acted as co-managers.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on February 10, 2016. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808-7525, ext. 6142; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact: Dan Budwick, Pure Communications [email protected] 973-271-6085 Investor Contact: Luke Heagle, Pure Communications [email protected] 910-726-1372
